ClinicalTrials.gg
RecruitingNCT07265921Solid TumorsUpdated Dec 5, 2025

A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

A Phase 1 interventional study of SIM0609 for injection and dose expansion of SIM0609 in CRC in Advanced Solid Cancer, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label,multicenter phase I study to evaluate the safety,Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0609 in Adult Participants with Locally Advanced/Metastatic Solid Tumors

02

Conditions studied

  • Advanced Solid Cancer
03

In context

Lead sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd. is the lead sponsor of 78 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation and signature of form;
  2. At least 18 years old, male or female;
  3. Participants with and/or cytologically confirmed locally advanced/ solid tumors;
  4. Participants should have at least one evaluable or measurable tumor lesion;
  5. Participants have failed the standard of therapy in the locally advanced/metastatic setting;
  6. (ECOG) performance score of 0 or 1;
  7. Expected survival ≥12 weeks;
  8. Adequate organ and bone marrow function;
  9. Availability of archival formalin-fixed, paraffin-embedded (FFPE) tumor tissue, or fresh within 28 days before first administration, is mandatory

Exclusion criteria

Exclusion Criteria:

  1. Active second primary within the previous 2 years except for localized cancers that are considered to have been cured and in the opinion of the Investigator present a low risk for recurrence;
  2. Symptomatic central nervous system (CNS) or requiring CNS-directed local therapy or treatment that occurred within 2 weeks prior to the first administration of the treatment;
  3. Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging screening;
  4. Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study ;
  5. Any active infections requiring systemic therapy within 2 weeks prior to the initiation of the study treatment;
  6. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring drainage or medical intervention within 4 weeks before the first dose of study treatment;
  7. Not recovered from previous anticancer therapy-induced AEs(Adverse Events);
  8. Currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of first dose of study treatment;
  9. Received prior therapies within the following time frames prior to the first dose of study treatment:

    1. Previous cytotoxic therapy, anticancer targeted small molecules within 2 weeks.
    2. Anti-cancer antibody, or ADC within 5 half-lives or 4 weeks (whichever is shorter).
    3. Chinese medicines/herbal preparations with anticancer indication taken within 2 weeks.
    4. Radiation therapy within 4 weeks.
  10. Prior exposure to topoisomerase I inhibitor (TOP1i)-based antibody drug conjugate (ADC) therapies or CDH17-targeted ADC therapies.
  11. Use of any therapy within 4 weeks prior to the first dose of study treatment.
  12. Administration of below medications ≤14 days prior to the first dose of study treatment.

    1. Strong or moderate inducers/inhibitors;
    2. Drugs with known risk of Torsades de Pointes(TdP);
    3. Drugs that may prolong the ;
  13. Major surgery within 2 weeks of receiving the first dose of study treatment;
  14. Known (HIV) infection or known acquired immunodeficiency syndrome ;
  15. Active or chronic or infection;
  16. Participants with cardiovascular diseases;
  17. History of allogeneic organ transplantation or ;
  18. History of to active or inactive of SIM0609 or drugs with a similar chemical structure or class to SIM0609;
  19. Pregnant or nursing (lactating) women;
  20. Male participants with female partners of , unless they are using highly effective methods from signing of to 180 days after the last dose of study treatment;
  21. Presence of any other condition that may increase the risk associate with study participant or may interfere with the interpretation of study results, and, in the opinion of the Investigator, would make the participant inappropriate for entry into the study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
232 participants (estimated)

Study arms

  • Experimental
    A dose escalation of SIM0609

    Multiple dose levels of SIM0609 will be explored in dose escalation, and determine the maximum tolerated dose.

    Drug: SIM0609 for injection

  • Experimental
    A dose expansion of SIM0609 -CRC cohort

    1\~3 dose levels of SIM0609 will be explored in dose expansion to evaluate the preliminary anti-tumor activity of SIM0609 in colorectal carcinoma (CRC)

    Drug: dose expansion of SIM0609 in CRC

  • Experimental
    A dose expansion of SIM0609-GC/GEJC cohort

    1\~3 dose levels of SIM0609 will be explored in dose expansion to evaluate the preliminary anti-tumor activity of SIM0609 in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC)

    Drug: dose expansion of SIM0609 in GC/GEJC cohort

  • Experimental
    A dose expansion of SIM0609-PDAC cohort

    1\~3 dose levels of SIM0609 will be explored in dose expansion to evaluate the preliminary anti-tumor activity of SIM0609 in pancreatic ductal adenocarcinoma (PDAC)

    Drug: dose expansion of SIM0609 in PDAC cohort

  • Experimental
    A dose expansion of SIM0609-positive other solid tumors cohort

    1\~3 dose levels of SIM0609 will be explored in dose expansion to evaluate the preliminary anti-tumor activity of SIM0609 in positive other solid tumors

    Drug: dose expansion of SIM0609 in positive other solid tumors

Interventions

  • DrugSIM0609 for injection

    Multiple dose levels of SIM0609 will be explored in dose escalation

  • Drugdose expansion of SIM0609 in CRC

    1\~3 dose levels of SIM0609 will be explored in dose expansion to evaluate the preliminary anti-tumor activity of SIM0609 in colorectal carcinoma (CRC)

  • Drugdose expansion of SIM0609 in GC/GEJC cohort

    1\~3 dose levels of SIM0609 will be explored in dose expansion in GC/GEJC cohort

  • Drugdose expansion of SIM0609 in PDAC cohort

    1\~3 dose levels of SIM0609 will be explored in dose expansion in PDAC cohort

  • Drugdose expansion of SIM0609 in positive other solid tumors

    1\~3 dose levels of SIM0609 will be explored in positive other solid tumors cohort

06

What researchers measure

Primary outcomes

  1. Dose escalation:Dose -limiting toxicity (DLT)

    Time frame: At the end of Cycle 1 (each cycle is 21/28days)

  2. Dose escalation:Safety and Tolerability

    Safety and tolerability: Incidence and severity of AEs and serious adverse events (SAEs) assessed by CTCAE v5.0, changes in laboratory values, vital signs, and ECGs. AE related dose interruptions, dose reduction and treatment discontinuation, dose intensity

    Time frame: 2 years

  3. Dose escalation: Objective response rate(ORR)

    Proportion of subjects who have a complete or partial response assessed by investigator per RECIST 1.1

    Time frame: 2 years

07

Study locations

1 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Dec 2028, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 5, 2025
StartActual
Nov 7, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Jun 2029
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07265921
Collaborators
Shanghai Xianwei Medical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Nov 7, 2025
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Dec 5, 2025

Study contacts

Jinxiu Zhang
Contact
zhangjinxiu@zaiming.com
86-010-65212241

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion